How does Genentech like it under Roche's wing?

Three years after the Roche ($RHHBY) buyout, how is Genentech faring as a unit of the Swiss company? It's in the midst of a "top-to-bottom redesign" in a "meticulously thought-out" process, Xconomy reports. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.